Drugs / Cotadutide
Cotadutide
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT05668936 | Jan → Mar 2023 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05517226 | Sep 2022 → Feb 2023 | — | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05294458 | Mar → Sep 2022 | chronic kidney disease, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05437848 | Feb → Dec 2022 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04208620 | Jan → Jul 2020 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04091373 | Sep 2019 → Mar 2020 | type 2 diabetes mellitus | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03625778 | Aug 2018 → Aug 2019 | obesity disorder | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03385369 | Jan → Apr 2018 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03347968 | Nov 2017 → Apr 2018 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03235375 | Oct 2017 → Apr 2018 | impaired renal function disease | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02394314 | Feb → Aug 2015 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02548585 | Dec 2015 → Feb 2017 | type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 211 trials · 7 met primary | ||||||
| Phase 2 | NCT05364931 | Jul 2022 → Apr 2024 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04515849 | Aug 2020 → Mar 2022 | chronic kidney disease, type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT04019561 | Sep 2019 → May 2021 | NAFLD1, metabolic dysfunction-associated steatohepatitis | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03745937 | Jan → May 2019 | type 2 diabetes mellitus | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03596177 | Sep 2018 → Dec 2019 | obesity disorder, type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 2 | NCT03645421 | Aug 2018 → Jan 2019 | type 2 diabetes mellitus | AstraZeneca | Completed | Mixed |
| Phase 2 | NCT03550378 | Jun 2018 → Feb 2019 | impaired renal function disease, type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 2 | NCT03555994 | May 2018 → Apr 2021 | type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 2 | NCT03444584 | May → Dec 2018 | type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 2 | NCT03244800 | Sep 2017 → Jan 2018 | type 2 diabetes mellitus | MedImmune LLC | Completed | Met primary |
| Phase 2 | NCT03235050 | Aug 2017 → May 2018 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-11 | AstraZeneca | Results AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020 astrazeneca.com ↗
An oral presentation of new Phase II data on investigational cotadutide, a dual receptor agonist with balanced GLP-1 and glucagon activity, showing positive effect on blood glucose levels and changes in liver fat and glycogen stores in patients with T2D (Abstract #354-OR) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-11 | AstraZeneca | AstraZeneca to showcase leadership in treating type-2 diabetes and cardiorenal complications at ADA 2020 astrazeneca.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cotadutide | “Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, has demonstrated robust improvements in body weight, glycemia, and hepatic...” PMID 38729399 ↗ May 202410“CONTEXT: Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity.” PMID 31608926 ↗ Mar 2020 “MEDI0382 (also known as Cotadutide) administered once daily subcutaneously (SC) for 28 days” NCT03555994 ↗ |
| Known as | Cotadutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297630 ↗ |
| Known as | MEDI0382 | “This is a Phase 1 study designed to assess the safety and tolerability of MEDI0382 (Cotadutide) in Japanese T2DM patients.” NCT04208620 ↗ |
| Action | Activate | “MEDI0382, a GLP-1 and glucagon receptor dual agonist” PMID 29945727 ↗ Jun 20182“Glucagon-like peptide 1 receptor agonist” CHEMBL4297630 ↗ “Glucagon receptor agonist” CHEMBL4297630 ↗ |
| Modality | Peptide | “a peptide co-agonist” PMID 38729399 ↗ May 2024 |
| Route | Subcutaneous | “MEDI0382 administered subcutaneously” NCT02394314 ↗ |
| Target | GCGR | “Glucagon receptor agonist” CHEMBL4297630 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL4297630 ↗ |